Projects
Explore our projects across different therapeutic fields.
Diversified Specialty Portfolio is our ultimate aspiration
The Company has formulated a structured roadmap to guide its next phase of growth in alignment with the objectives of Vision 2030 and the National Biotechnology Strategy. These plans are designed to expand domestic pharmaceutical manufacturing, promote localisation of high-value and technologically advanced therapies and enhance the Kingdom’s self-sufficiency in critical healthcare segments. The roadmap integrates the Company’s operational strengths in oncology and specialty medicines with new investments in biologics, insulin, respiratory products, vaccines and advanced therapies. Each initiative is intended to strengthen the Company’s technological base, broaden its therapeutic reach and position it as a long-term contributor to national healthcare resilience and industrial diversification.
Oncology Project
specialized manufacturing plant that focuses on the manufacturing of highly specialized and technically advanced pharmaceutical products to create a new pharmaceutical industrial era in KSA and MENA region and to be the 1st Saudi.
Oncology specialized pharmaceutical company with a manufacturing facility in KSA. Oncology market volume is almost 2.57 Bn SR in 2019 , with consistent CAGR of 6%, expected to reach 2.73 Bn SR in 2020. Project’s scope is to be a partner with the government in decreasing the expenditure of the healthcare sector via the provision of products with International Standard Quality and Affordable Prices. The production area is 2,826.90 m2 & the Storage area is 1,848.60 m2. Refrigerated stores area (2 to 8 °C) is 70.30 m2. Manufacturing Capacity (Production Lines):
Tablet: 300M
Capsule: 150M
Sterile liquid: 9M
Lyophilized vial: 6M
Note: The production capacity based on operating one shift per day. When required, the Company is able to operate up to three shifts per day
Insulin Facility
The Company’s insulin localisation initiative addresses one of the Kingdom’s most pressing healthcare priorities – the rising prevalence of diabetes. Through a phased roadmap transitioning from secondary packaging to full compounding, filling and formulation, the project will reduce the Kingdom’s reliance on imported insulin and establish the Company as the first domestic insulin manufacturer. Commercial operations are ramping up from 2024G, with full-scale manufacturing targeted for 2028G. The insulin platform offers stable, recurring volumes, cost efficiencies through localisation and preferential access to government tenders, supported by national policies promoting insulin self-sufficiency under Vision 2030 and the National Biotechnology Strategy.
Biosimilars and Monoclonal Antibodies Facility
Biologics represent the fastest-growing segment of the global and Saudi pharmaceutical markets, particularly in oncology, immunology and chronic diseases. The Company’s biosimilars and monoclonal antibodies facility is structured around a value-driven approach, prioritising molecules based on commercial potential, patent expiries, partner quality and competitive positioning. The facility encompasses biomanufacturing capabilities for purification, aseptic filling and quality control in compliance with EMA, FDA and SFDA standards. This platform establishes a first-mover advantage in local biologics manufacturing, reducing import dependency and providing scalable export potential across MENA. By integrating strategic product selection with advanced infrastructure, the Company positions itself to capture sustainable growth in high-value therapeutic categories.
Respiratory Facility
Respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), continue to represent significant unmet medical needs in the Kingdom. The Company’s respiratory manufacturing project, the first dedicated local facility of its kind, will produce dry-powder inhalers, metered-dose inhalers, soft-mist devices and sterile nebulised solutions. This localisation initiative supports long-term, chronic-care treatment markets, offering predictable recurring revenues while addressing national healthcare priorities. By establishing domestic production for technically complex respiratory products, the facility strengthens drug security, enhances cost efficiency and positions the Company competitively within a segment traditionally dominated by imports.
Oncology Project
Specialized manufacturing plant that focuses on the manufacturing of highly specialized and technically advanced pharmaceutical products to create a new pharmaceutical industrial era in KSA and MENA region and to be the 1st Saudi.
Oncology specialized pharmaceutical company with a manufacturing facility in KSA. Oncology market volume is almost 2.57 Bn SR in 2019 , with consistent CAGR of 6%, expected to reach 2.73 Bn SR in 2020. Project’s scope is to be a partner with the government in decreasing the expenditure of the healthcare sector via the provision of products with International Standard Quality and Affordable Prices. The production area is 2,826.90 m2 & the Storage area is 1,848.60 m2. Refrigerated stores area (2 to 8 °C) is 70.30 m2. Manufacturing Capacity (Production Lines):
Tablet: 300M
Capsule: 150M
Sterile liquid: 9M
Lyophilized vial: 6M
Note: The production capacity based on operating one shift per day. When required, the Company is able to operate up to three shifts per day
Insulin Facility
The Company’s insulin localisation initiative addresses one of the Kingdom’s most pressing healthcare priorities – the rising prevalence of diabetes. Through a phased roadmap transitioning from secondary packaging to full compounding, filling and formulation, the project will reduce the Kingdom’s reliance on imported insulin and establish the Company as the first domestic insulin manufacturer. Commercial operations are ramping up from 2024G, with full-scale manufacturing targeted for 2028G. The insulin platform offers stable, recurring volumes, cost efficiencies through localisation and preferential access to government tenders, supported by national policies promoting insulin self-sufficiency under Vision 2030 and the National Biotechnology Strategy.
Biosimilars and Monoclonal Antibodies Facility
Biologics represent the fastest-growing segment of the global and Saudi pharmaceutical markets, particularly in oncology, immunology and chronic diseases. The Company’s biosimilars and monoclonal antibodies facility is structured around a value-driven approach, prioritising molecules based on commercial potential, patent expiries, partner quality and competitive positioning. The facility encompasses biomanufacturing capabilities for purification, aseptic filling and quality control in compliance with EMA, FDA and SFDA standards. This platform establishes a first-mover advantage in local biologics manufacturing, reducing import dependency and providing scalable export potential across MENA. By integrating strategic product selection with advanced infrastructure, the Company positions itself to capture sustainable growth in high-value therapeutic categories.
Respiratory Facility
Respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), continue to represent significant unmet medical needs in the Kingdom. The Company’s respiratory manufacturing project, the first dedicated local facility of its kind, will produce dry-powder inhalers, metered-dose inhalers, soft-mist devices and sterile nebulised solutions. This localisation initiative supports long-term, chronic-care treatment markets, offering predictable recurring revenues while addressing national healthcare priorities. By establishing domestic production for technically complex respiratory products, the facility strengthens drug security, enhances cost efficiency and positions the Company competitively within a segment traditionally dominated by imports.